

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of:	<i>)</i> \
Lieven J. STUYVER.) Group Art Unit: 1623
Application No.: 10/045,292)) Examiner: Traviss C. McIntosh, III \
Filed: October 18, 2001) Confirmation No.: 4833
For: MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION	<i>)</i>)))

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In an Office Action dated April 19, 2006, the Examiner required restriction under 35 U.S.C. § 121 between the following groups of claims:

- I. Claims 1, 2, and 44, allegedly drawn to methods of treating viral infections using compounds of formula Ia, classified in class 514, subclass 49.
- II. Claims 1, 3, and 44, allegedly drawn to methods of treating viral infections using compounds of formula lb, classified in class 514, subclass 45.
- III. Claims 1 and 44, allegedly drawn to methods of treating viral infections using compounds of formula lc, classified in class 514, subclass 43.
- IV. Claims 1, 4, and 44, allegedly drawn to methods of treating viral infections using compounds of formula IIa, classified in class 514, subclass 49.